SEC Form 4 · accession 0001415889-16-006614
MABVAX THERAPEUTICS HOLDINGS, INC. · MBVX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey F Eisenberg
Director
Period of report
Jun 29, 2016
Accepted (ET)
Jul 28, 2016 · 5:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001109196
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2 | $0.55 | Jun 29, 2016 | A | 35,000 | A | — | Jun 29, 2026 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F1Automatic Annual Grant to Non-Employee Director pursuant to the Issuer's Non-Employee Director Compensation Policy
- F2Option vests and becomes exercisable one year after the date of grant.